Scinai Immunotherapeutics (SCNI) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significant bank loan into equity to secure its Nasdaq listing compliance, expected by August 23, 2024. The company also reported confidence in their contract development and manufacturing organization (CDMO) services, with projected sales growth following positive market engagement and development milestones in its pipeline, including promising results for a psoriasis treatment and strategic partnership pursuits for its NanoAb therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
